Open-Source, Step-Counting Algorithm for Smartphone Data Collected in Clinical and Nonclinical Settings: Algorithm Development and Validation Study.

IF 3.3 Q2 ONCOLOGY JMIR Cancer Pub Date : 2023-11-15 DOI:10.2196/47646
Marcin Straczkiewicz, Nancy L Keating, Embree Thompson, Ursula A Matulonis, Susana M Campos, Alexi A Wright, Jukka-Pekka Onnela
{"title":"Open-Source, Step-Counting Algorithm for Smartphone Data Collected in Clinical and Nonclinical Settings: Algorithm Development and Validation Study.","authors":"Marcin Straczkiewicz, Nancy L Keating, Embree Thompson, Ursula A Matulonis, Susana M Campos, Alexi A Wright, Jukka-Pekka Onnela","doi":"10.2196/47646","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Step counts are increasingly used in public health and clinical research to assess well-being, lifestyle, and health status. However, estimating step counts using commercial activity trackers has several limitations, including a lack of reproducibility, generalizability, and scalability. Smartphones are a potentially promising alternative, but their step-counting algorithms require robust validation that accounts for temporal sensor body location, individual gait characteristics, and heterogeneous health states.</p><p><strong>Objective: </strong>Our goal was to evaluate an open-source, step-counting method for smartphones under various measurement conditions against step counts estimated from data collected simultaneously from different body locations (\"cross-body\" validation), manually ascertained ground truth (\"visually assessed\" validation), and step counts from a commercial activity tracker (Fitbit Charge 2) in patients with advanced cancer (\"commercial wearable\" validation).</p><p><strong>Methods: </strong>We used 8 independent data sets collected in controlled, semicontrolled, and free-living environments with different devices (primarily Android smartphones and wearable accelerometers) carried at typical body locations. A total of 5 data sets (n=103) were used for cross-body validation, 2 data sets (n=107) for visually assessed validation, and 1 data set (n=45) was used for commercial wearable validation. In each scenario, step counts were estimated using a previously published step-counting method for smartphones that uses raw subsecond-level accelerometer data. We calculated the mean bias and limits of agreement (LoA) between step count estimates and validation criteria using Bland-Altman analysis.</p><p><strong>Results: </strong>In the cross-body validation data sets, participants performed 751.7 (SD 581.2) steps, and the mean bias was -7.2 (LoA -47.6, 33.3) steps, or -0.5%. In the visually assessed validation data sets, the ground truth step count was 367.4 (SD 359.4) steps, while the mean bias was -0.4 (LoA -75.2, 74.3) steps, or 0.1%. In the commercial wearable validation data set, Fitbit devices indicated mean step counts of 1931.2 (SD 2338.4), while the calculated bias was equal to -67.1 (LoA -603.8, 469.7) steps, or a difference of 3.4%.</p><p><strong>Conclusions: </strong>This study demonstrates that our open-source, step-counting method for smartphone data provides reliable step counts across sensor locations, measurement scenarios, and populations, including healthy adults and patients with cancer.</p>","PeriodicalId":45538,"journal":{"name":"JMIR Cancer","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687676/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/47646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Step counts are increasingly used in public health and clinical research to assess well-being, lifestyle, and health status. However, estimating step counts using commercial activity trackers has several limitations, including a lack of reproducibility, generalizability, and scalability. Smartphones are a potentially promising alternative, but their step-counting algorithms require robust validation that accounts for temporal sensor body location, individual gait characteristics, and heterogeneous health states.

Objective: Our goal was to evaluate an open-source, step-counting method for smartphones under various measurement conditions against step counts estimated from data collected simultaneously from different body locations ("cross-body" validation), manually ascertained ground truth ("visually assessed" validation), and step counts from a commercial activity tracker (Fitbit Charge 2) in patients with advanced cancer ("commercial wearable" validation).

Methods: We used 8 independent data sets collected in controlled, semicontrolled, and free-living environments with different devices (primarily Android smartphones and wearable accelerometers) carried at typical body locations. A total of 5 data sets (n=103) were used for cross-body validation, 2 data sets (n=107) for visually assessed validation, and 1 data set (n=45) was used for commercial wearable validation. In each scenario, step counts were estimated using a previously published step-counting method for smartphones that uses raw subsecond-level accelerometer data. We calculated the mean bias and limits of agreement (LoA) between step count estimates and validation criteria using Bland-Altman analysis.

Results: In the cross-body validation data sets, participants performed 751.7 (SD 581.2) steps, and the mean bias was -7.2 (LoA -47.6, 33.3) steps, or -0.5%. In the visually assessed validation data sets, the ground truth step count was 367.4 (SD 359.4) steps, while the mean bias was -0.4 (LoA -75.2, 74.3) steps, or 0.1%. In the commercial wearable validation data set, Fitbit devices indicated mean step counts of 1931.2 (SD 2338.4), while the calculated bias was equal to -67.1 (LoA -603.8, 469.7) steps, or a difference of 3.4%.

Conclusions: This study demonstrates that our open-source, step-counting method for smartphone data provides reliable step counts across sensor locations, measurement scenarios, and populations, including healthy adults and patients with cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
开源,用于临床和非临床环境中收集的智能手机数据的计步算法:算法开发和验证研究。
背景:步数在公共卫生和临床研究中越来越多地用于评估幸福感、生活方式和健康状况。然而,使用商业活动跟踪器估计步数有几个限制,包括缺乏再现性、通用性和可伸缩性。智能手机是一个潜在的有前途的替代方案,但它们的计步算法需要强大的验证,以考虑时间传感器的身体位置、个人步态特征和异质健康状态。目的:我们的目标是评估一种开源的智能手机计步法,在不同的测量条件下,根据从不同身体位置同时收集的数据估计的步数(“跨身”验证),人工确定的地面真相(“视觉评估”验证),以及来自晚期癌症患者的商业活动追踪器(Fitbit Charge 2)的步数(“商业可穿戴”验证)。方法:我们使用8个独立的数据集,分别在受控、半受控和自由生活环境中收集,在典型的身体位置携带不同的设备(主要是Android智能手机和可穿戴加速度计)。共有5个数据集(n=103)用于跨体验证,2个数据集(n=107)用于视觉评估验证,1个数据集(n=45)用于商业可穿戴验证。在每种情况下,步数都是使用先前发布的智能手机步数计数方法来估计的,该方法使用原始的亚秒级加速度计数据。我们使用Bland-Altman分析计算步数估计值和验证标准之间的平均偏倚和一致限(LoA)。结果:在跨体验证数据集中,参与者执行751.7 (SD 581.2)步,平均偏差为-7.2 (LoA -47.6, 33.3)步,或-0.5%。在视觉评估的验证数据集中,地面真实步数为367.4 (SD 359.4)步,而平均偏差为-0.4 (LoA -75.2, 74.3)步,或0.1%。在商业可穿戴验证数据集中,Fitbit设备显示的平均步数为1931.2 (SD 2338.4),而计算偏差等于-67.1 (LoA -603.8, 469.7)步,或相差3.4%。结论:本研究表明,我们的开源智能手机数据步数方法可以在传感器位置、测量场景和人群(包括健康成年人和癌症患者)中提供可靠的步数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
JMIR Cancer
JMIR Cancer ONCOLOGY-
CiteScore
4.10
自引率
0.00%
发文量
64
审稿时长
12 weeks
期刊最新文献
A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study. Lessons Learned From Shared Decision-Making With Oral Anticoagulants: Viewpoint on Suggestions for the Development of Oral Chemotherapy Decision Aids. A Smart Water Bottle and Companion App (HidrateSpark 3) to Improve Bladder-Filling Compliance in Patients With Prostate Cancer Receiving Radiotherapy: Nonrandomized Trial of Feasibility and Acceptability. Telemedicine Applications for Cancer Rehabilitation: Scoping Review. Health Information Seeking on the Internet Among Patients With and Without Cancer in a Region Affected by the 2011 Fukushima Triple Disaster: Cross-Sectional Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1